advanced cancer (all indications)
Conditions
Interventions
Group 1: Determination of the sensitivity of tumor tissue to investigational anti-cancer drugs based on the DRP® method
Sponsors
Oncology Venture ApS
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: i. Histological or cytological documented locally advanced or metastatic solid tumor relapsed on 1 or more different prior therapies ii. Age = 18 years iii. Written informed consent iv. Life expectancy = 6 months v. ECOG Performance status = 1 vi. FFPE tumor tissue available
Exclusion criteria
Exclusion criteria: i. Other primary malignancy within the last 5 years prior to enrolment, except for adequately treated squamous cell carcinoma of the skin, or adequately controlled limited basal cell skin cancer. ii. Evidence of any other disease or psychological dysfunction giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect patients understanding of the information, compliance with study routines, or place the patient at high risk from treatment related complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify cancer patients with different indications with high likelihood of being sensitive to investigational cancer drugs, based on DRP® pre-screening of archival formalin-fixed paraffin embedded (FFPE) cancer tumor tissue from the time of diagnosis and/or the most recent re-biopsy, if available. | — |
Secondary
| Measure | Time frame |
|---|---|
| To utilize the DRP® to do retrospective analysis of whether the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs used in the treatment of cancer as well as prospective analyses guiding the Investigators on future treatments. | — |
Countries
Germany
Contacts
Public ContactMaren Keller
Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie
Outcome results
None listed